Metagen Therapeutics

Biotech & Life Sciences · Tsuruoka-Shi, Japan · Founded 2020

Microbiome-based therapeutics for various intractable diseases. MoreLess

Metagen Therapeutics (MGTx) is a clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies. The company combines proprietary paired metagenomic datasets with AI/ML-driven donor-recipient matching to advance precision microbiome medicine across ulcerative colitis, immuno-oncology, and neurodegenerative disease.

Headquartered in Tsuruoka, Japan, MGTx leverages a cross-border regulatory strategy spanning PMDA and FDA pathways, positioning it as a platform bridging Japanese clinical innovation with global market access.

Valuation $0–100M

Headcount <100

Total funding $10–50M

Unlock exact values

Company overview

Metagen Therapeutics company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2020
Headquarters: Tsuruoka-Shi, Japan
Employees: 18
Open positions: None listed
Dealroom signal: 62.1

Website ↗LinkedIn ↗

client focusb2btechnologyArtificial Intelligencesub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorCore AIsectorSpinoutsectorBiotech and PharmasectorGenerative AIsectorDT and LSsectorscience-based

Valuation & funding

Metagen Therapeutics funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jan 2026	$9.2M	$37M	Canon Marketing Japan MIRAI Fund · Medipal Innovation Fund · Asuka Innovation Fund · Matsukiyo Cocokara	—
SERIES B✓Equity / VC	Sep 2025	$18M	$72M	SMBC Venture Capital · Dentsu Ventures · Mirai Creation fund · JAFCO	—
SERIES A✓Equity / VC	Jun 2023	$13M	$53M	Nippon Venture Capital · Fast Track Initiative · JIC Venture Growth Investments · SMBC Venture Capital	—
SEED✓Equity / VC	Oct 2022	$1.1M	$4.3M	JAFCO · Fast Track Initiative · Keio Innovation Initiative	—
SEED✓Equity / VC	Jun 2022	$385K	$1.5M	Keio Innovation Initiative · Fast Track Initiative	—
SEEDEquity / VC	Mar 2021			Keio Innovation Initiative · Fast Track Initiative	—
SPINOUT✓Other financing	Jan 2020			Tokyo Institute of Technology · Keio University · Juntendo University	—

Showing 7 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

Year	Employees
2026	18
2025	38
2024	24
2023	15
2022	6
2021	7
2020	5

Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Metagen Therapeutics website traffic

Latest recorded traffic for Metagen Therapeutics is 4.4K monthly website visits, up 46.7% over the last three months. Metagen Therapeutics's team declined 52.6% over the past year.

Latest monthly visits4.4K 3-month web change+46.7% 1-year team growth-52.6%

Monthly website visits45 observations · Nov 2022–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Metagen Therapeutics compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DBDiffuse BioWe're building push-button software for drug design, driven by breakthroughs in generative AI	San Francisco, United States	Operational	11	$125K	$500K
VIVilyaDeveloping a novel class of drugs that precisely target the biology of disease	Seattle, United States	Operational
MAMenten AILeverages synthetic biology, machine learning and quantum computing to create new proteins not found in nature for diverse applications in the pharmaceutical and chemical industries	San Francisco, United States	Operational
EVEvozyneGenerative AI-powered drug discovery platform and product development	Chicago, United States	Operational
RERevrFormerly Tierra Biosciences. Accelerates bio-discovery using cell-free systems combined with powerful automation tools for data generation	San Leandro, United States	Operational
1S10x ScienceAI-native platform for next-generation protein characterization	San Francisco, United States	Operational
IBiCamuno BiotherapeuticsAI-driven iPSC therapies for cancer and neurological disorders.	Jiuquan, China	Operational
DRDreamFoldDeveloping generative machine learning algorithms to navigate the vast space of proteins to discover medicines	Montreal, Canada	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Metagen Therapeutics's talent

Book a demo to see the people

Team profiled 5 named & role-tagged

Founders /100 quality score

Key operators 4 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

19 investors on Metagen Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Seed 3 investors entered at this stage

Keio Innovation Initiative

Fast Track Initiative

JAFCO

Series A 13 investors entered at this stage

Nippon Venture Capital

JIC Venture Growth Investments

SMBC Venture Capital

Mirai Creation fund

Mizuho Capital

Dentsu Ventures

Mirai Sozo Capital

Japan Bank for International Cooperation

Canon Marketing Japan MIRAI Fund

Medipal Innovation Fund

Asuka Innovation Fund

Matsukiyo Cocokara

Green Co-Invest Investment

Other known 3 additional known investors

Juntendo University

Keio University

Tokyo Institute of Technology

Global footprint

Where Metagen Therapeutics has talent and traffic

Workforce by country

1 countries with
team presence

🇯🇵 Japan100%

1 country shown

In the news

Latest news about Metagen Therapeutics

Recent press, funding announcements, and product moves mentioning Metagen Therapeutics — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Metagen Therapeutics

An AI-synthesized read of the highest-engagement posts about Metagen Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Metagen Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.